SEPTODONT
GenericsSEPTODONT is a generic drug manufacturer focused on Gastroenterology.
SEPTODONT's Key Drugs
SEPTODONT's core commercial portfolio centers on DYCLOPRO, PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, spanning Gastroenterology — its most strategically important drugs approved in the last 15 years.
SEPTODONT's Recent FDA Approvals
New NDA/BLA approvals for SEPTODONT over the last two years — novel drugs only, excluding generics and label supplements.
SEPTODONT's Therapeutic Areas
SEPTODONT's approved drugs and pipeline span 1 therapeutic area, led by Gastroenterology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SEPTODONT's Top Competitors
SEPTODONT's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SEPTODONT Pipeline Snapshot
Active clinical trials for SEPTODONT across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DYCLOPRO leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Gastroenterology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 1972-10-17
- Latest
- 2019-11-26
- Applications
- 8